By Angie Wong
For millions of people, a serious diagnosis comes with two types of fear. First, there is the fear of the disease — the cancer, the Crohn’s, the rheumatoid arthritis. But quickly, a second, sharper fear takes over: Will I be able to afford the help I need?
I’ve witnessed friends and family discover the exorbitant price of biologic drugs, the cutting-edge, life-saving treatments that countless patients rely on, and feel their world crumble beneath them. These medicines are miracles of science, but when they cost tens of thousands of dollars a year, they feel less like a "cure" and more like a debt sentence.
That is why the rise of biosimilars coming to market feels like a long-overdue light at the end of the tunnel.
For those who aren’t familiar, biosimilar drugs work like generic versions of brand-name biologics. They undergo the same rigorous FDA testing and work exactly like the original drugs. But for a patient, the real difference is the price. Because they introduce competition into a market long dominated by a single manufacturer, they cost less — sometimes a lot less.
The numbers tell a story of hope. In 2024 alone, biosimilars saved patients and the healthcare system $20.2 billion. Since 2015, patients and the healthcare system have saved $56.2 billion. For a senior on Medicare or a parent with a high-deductible plan, these aren’t just "savings" — they are the difference between staying on a life-saving regimen or being forced to skip doses to keep the lights on.
It’s heartening to see that leaders are finally listening, with President Trump’s 2025 executive order, Lowering Drug Prices by Once Again Putting Americans First, a real turning point. It signaled that the government is finally prioritizing market competition over corporate protectionism. When the FDA recently moved to make it faster and cheaper to bring these biosimilar drugs to market, it wasn't just a win for policy experts, it was a win for every patient sitting at a kitchen table trying to figure out their medical bills.
When medicine is affordable, patients can finally focus on getting better. A grandparent fighting cancer shouldn’t have to worry about leaving their family in debt. A parent managing an autoimmune disease shouldn’t have to choose between a refill and a grocery run.
Biosimilars mean you don't have to choose. They offer the same safety, the same effectiveness, but at a price that respects the American worker. If we are serious about making healthcare accessible, we have to keep pushing for these alternatives. For millions of people each year, it’s more than just good politics; it’s the ability to live a healthy life without going broke.
Angie Wong is a Miami Republican Committeewoman, political commentator, and columnist. She has over twenty years of experience in investigative journalism, and contributes regularly to the NY Post, as well as appearing on other networks, including Fox News, One America News, BBC, and Newsmax.
